Global Xerostomia Therapeutics Market Overview
As per MRFR analysis, the xerostomia therapeutics market Size was estimated at 0.72 (USD Billion) in 2022. The xerostomia therapeutics market is expected to grow from 0.78 (USD Billion) in 2023 to 1.65 (USD Billion) by 2032. The xerostomia therapeutics market CAGR (growth rate) is expected to be around 8.67% during the forecast period (2024 - 2032).
Key Xerostomia Therapeutics Market Trends Highlighted
Key market drivers include the rising prevalence of xerostomia, an increasing geriatric population, and advancements in therapeutic approaches.
The growing demand for effective and safe treatments for xerostomia presents opportunities for pharmaceutical companies and healthcare providers to explore innovative solutions.
Recent trends showcase a shift toward personalized treatment strategies, including salivary gland transplantation and gene therapy.
The development and commercialization of novel drugs, such as pilocarpine and cevimeline, have also expanded the treatment options available for xerostomia patients.
Furthermore, advancements in drug delivery systems, such as sustained-release formulations and topical applications, have improved patient compliance and treatment outcomes.
The collaborative efforts of researchers, clinicians, and pharmaceutical companies are expected to drive continued innovation and growth in the xerostomia therapeutics market in the coming years.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Xerostomia Therapeutics Market Drivers
Rising Prevalence of Xerostomia
Xerostomia, also known as dry mouth, is a medical condition that occurs due to the lack of saliva. It causes various oral health issues.
One of the main drivers of the xerostomia therapeutics market is the increasing prevalence of the condition.
Many factors contribute to this trend, including the growing number of older people who are more likely to experience xerostomia and the broader use of medication that has dry mouth as a side effect.
In addition, the prevalence of specific medical conditions leading to dry mouth is also on the rise. They include Sjogren’s syndrome, which contributes to the development of chronic xerostomia in up to 40% of patients, and diabetes.
With the increasing number of people suffering from xerostomia, the demand for therapeutics and other types of products will grow, driving the expansion of the market.
In the same way, the xerostomia therapeutics market will likely experience notable growth over the forecast period.
Growing Awareness of Xerostomia and its Impact
There is a growing awareness of xerostomia and its impact on oral health. This increased awareness is driven by various factors, including educational campaigns by healthcare professionals, media coverage, and advancements in diagnostic techniques.
As individuals become more informed about the condition, they are more likely to seek treatment, leading to increased demand for xerostomia therapeutics.
The xerostomia therapeutics market is expected to experience substantial growth in the coming years due to the rising awareness of xerostomia and its impact.
Advancements in Xerostomia Therapeutics
Xerostomia therapeutics has advanced tremendously in recent years. The emergence of new medications such as saliva substitutes and secretagogues has greatly improved the therapeutics of the disease. Moreover, significant steps have been made to understand the etiology of the disease.
The improved knowledge of the cause has facilitated the development of therapies that are specifically directed toward the cause. All these advancements have been great in enhancing the efficacy of the xerostomia treatment.
Moreover, they have played a significant role in the growth of the global xerostomia Market. The xerostomia therapeutics market is expected to grow over the forecast period at a steady pace.
Xerostomia Therapeutics Market Segment Insights
Xerostomia Therapeutics Market Drug Type Insights
Salivary substitutes, salivary stimulants, anticholinergics, pilocarpine, and cevimeline are the key drug types in the xerostomia therapeutics market. Salivary substitutes are the most used treatment for xerostomia, and they replace the saliva that is not being produced by the salivary glands.
Salivary stimulants act by stimulating the salivary glands to produce saliva. Anticholinergics act by inhibiting the action of the neurotransmitter acetylcholine, which inhibits secretion of saliva by the salivary glands. Both pilocarpine and cevimeline are muscarinic agonists, which means that they act to stimulate the muscarinic receptors in the salivary glands.
The xerostomia therapeutics market is expected to grow in the years to come. This growth may be attributed to the rising prevalence of xerostomia and the increasing demand for reliable treatments. The market is composed of the following five major drugs: salivary substitutes, salivary stimulants, anticholinergics, pilocarpine and cevimeline.
Salivary substitutes are expected to have the largest share of the market in 2023 due to their market value of about USD 0.45 billion. Salivary stimulants will be the fastest growing segment in the market with a CAGR of about 9.5% in the years to come.
There are several major players in the xerostomia therapeutics market. The major players in the market include GlaxoSmithKline, Pfizer, Novartis, and Teva Pharmaceuticals. All these companies invest significantly in research and development, and they always introduce new and innovative products in the market.
The market is also expected to witness a number of mergers and acquisitions in the years to come. This is because many companies will want to protect their position and market share.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Xerostomia Therapeutics Market Route of Administration Insights
The xerostomia therapeutics market has been divided by Route of Administration into Oral, Sublingual, Topical, and Injection sections. Of these, the Oral segment is likely to rise as a leading segment in the xerostomia therapeutics market in the coming years.
However, the Sublingual segment is also likely to exhibit a substantial rise, as the demand for sublingual tablets, films and devices is increasing among the population.
The Topical sector is likely to exhibit a steady growth rate in the coming years. The Injection segment is expected to hold a small yet steady share of the xerostomia therapeutics market.
Xerostomia Therapeutics Market Disease Indication Insights
The xerostomia therapeutics market is segmented by Disease Indication into Sjgren's Syndrome, Radiation Therapy-Induced Xerostomia, Medications-Induced Xerostomia, and Others. Sjgren's Syndrome is an autoimmune disorder that affects the exocrine glands, leading to dry mouth and dry eyes.
Radiation Therapy-Induced Xerostomia is a side effect of radiation therapy for head and neck cancers, which can damage the salivary glands and lead to dry mouth. Medications-Induced Xerostomia is a side effect of certain medications, such as antidepressants and antihistamines, which can block the production of saliva.
Other causes of xerostomia include diabetes, HIV/AIDS, and sarcoidosis. In 2023, the xerostomia therapeutics market was valued at USD 0.78 billion. The growth of the market is attributed to the increasing prevalence of Sjgren's Syndrome and Radiation Therapy-Induced Xerostomia, as well as the rising demand for effective treatments for dry mouth.
Sjgren's Syndrome is the leading cause of xerostomia, accounting for approximately 60% of cases. The prevalence of Sjgren's Syndrome is increasing worldwide, with an estimated 3 million people affected in the United States alone.
Radiation Therapy-Induced Xerostomia is another major cause of xerostomia, affecting approximately 50% of patients who undergo radiation therapy for head and neck cancers.
The xerostomia therapeutics market is a competitive landscape with a number of major players, including Biogen, Inc., Eli Lilly and Company, and GlaxoSmithKline plc. These companies are developing new and innovative treatments for xerostomia, such as saliva substitutes, saliva stimulants, and gene therapies.
Xerostomia Therapeutics Market Distribution Channel Insights
Distribution channels play a critical role in the xerostomia therapeutics market, with varying market shares and growth prospects across different channels.
Hospital pharmacies account for a significant share of the market, estimated to be around 38% in 2023 and projected to grow at a CAGR of 8.3% to reach a valuation of USD 0.63 billion by 2032.
This growth is attributed to the high volume of xerostomia patients treated in hospitals and the convenience of dispensing medications directly to patients. Retail pharmacies represent another important distribution channel, with a market share of approximately 29% in 2023.
This segment is expected to grow at a CAGR of 8.7% over the forecast period, reaching a valuation of USD 0.48 billion by 2032. The growth is driven by the increasing availability of over-the-counter xerostomia products and the convenience of purchasing medications without a prescription.
Online pharmacies are gaining traction in the xerostomia therapeutics market, with a market share of around 16% in 2023. The segment is projected to grow at a CAGR of 10.2% during the forecast period, reaching a valuation of USD 0.27 billion by 2032.
The growth is attributed to the increasing adoption of e-commerce platforms, the convenience of online shopping, and the wider availability of Xerostomia products online.
Xerostomia Therapeutics Market Regional Insights
The xerostomia therapeutics market is segmented into North America, Europe, Asia-Pacific, South America, and the Middle East and Africa. North America held the largest market share in 2023 and is expected to continue to dominate the market throughout the forecast period.
The high prevalence of xerostomia in the region, as well as the presence of a large number of key players, are major factors driving the growth of the market in North America. Europe is the second-largest market for xerostomia therapeutics and is expected to grow at a steady pace over the forecast period.
The rising geriatric population in the region, as well as the increasing awareness of xerostomia, are key factors driving the growth of the market in Europe. The Asia-Pacific region is expected to witness the fastest growth in the xerostomia therapeutics market over the forecast period.
The increasing prevalence of xerostomia in the region, as well as the growing awareness of the condition, are major factors driving the growth of the market in Asia-Pacific.
South America, the Middle East, and Africa are expected to account for a relatively small share of the xerostomia therapeutics market over the forecast period.
However, the rising prevalence of xerostomia in these regions, as well as the increasing awareness of the condition, are expected to drive growth in the market in these regions.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Xerostomia Therapeutics Market Key Players and Competitive Insights
Major players in the xerostomia therapeutics market are continuously focusing on developing new products to cater to the evolving needs of patients and healthcare professionals. Leading xerostomia therapeutics market players are investing in research and development to come up with innovative solutions that can effectively and safely manage xerostomia.
The competitive landscape of the xerostomia therapeutics market is characterized by a mix of established players and emerging entrants. Strategic partnerships and collaborations are becoming increasingly common as companies seek to expand their product portfolio and gain a competitive edge.
The xerostomia therapeutics market is expected to witness significant growth over the coming years, driven by the rising prevalence of conditions associated with xerostomia, such as Sjgren's syndrome and radiation therapy.
One of the leading players in the xerostomia therapeutics market is Biotene. The company offers a wide range of products, including mouthwashes, sprays, gels, and lozenges, that are designed to relieve the symptoms of xerostomia.
Biotene's products are available in over 50 countries worldwide and are trusted by healthcare professionals and patients alike. The company is committed to providing innovative and effective solutions for people suffering from dry mouth.
A notable competitor in the xerostomia therapeutics market is Salix Pharmaceuticals. The company's product portfolio includes prescription medications, such as pilocarpine and cevimeline, that are used to treat the symptoms of xerostomia.
Salix Pharmaceuticals is also actively involved in research and development and is currently evaluating new therapies for xerostomia. The company's commitment to innovation is evident in its strong pipeline of potential new products.
Key Companies in the xerostomia therapeutics market Include
- Medtronic
- GAMBRO
- Fresenius SE Co. KGaA
- DiaSorin S.p.A.
- Organ Recovery Systems, Inc.
- Toray Medical Co., Ltd.
- CaridianBCT, Inc.
- Cytosorbents Corporation
- Terumo Corporation
- Bellco
- Asahi Kasei Corporation
- Baxter International Inc.
- Nipro Corporation
- Kaneka Corporation
- Braun Melsungen AG
Xerostomia Therapeutics Market Developments
The rising prevalence of xerostomia due to increasing cancer treatments and medications, growing awareness about the condition, and technological advancements in drug development are key factors driving market growth.
Recent news developments include the FDA approval of Evomela for the treatment of radiation-induced severe oral mucositis, which can lead to xerostomia, and the initiation of clinical trials for novel therapies such as salivary gland transplantation and gene therapy. These advancements are expected to further fuel market expansion in the coming years.
Xerostomia Therapeutics Market Segmentation Insights
Xerostomia Therapeutics Market Drug Type Outlook
- Salivary Substitutes
- Salivary Stimulants
- Anticholinergics
- Pilocarpine
- Cevimeline
Xerostomia Therapeutics Market Route of Administration Outlook
- Oral
- Sublingual
- Topical
- Injection
Xerostomia Therapeutics Market Disease Indication Outlook
- Sjgren's Syndrome
- Radiation Therapy-Induced Xerostomia
- Medications-Induced Xerostomia
- Other
Xerostomia Therapeutics Market Distribution Channel Outlook
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Xerostomia Therapeutics Market Regional Outlook
- North America
- Europe
- South America
- Asia Pacific
- Middle East and Africa
| Report Attribute/Metric |
Details |
| Market Size 2022 |
0.72(USD Billion) |
| Market Size 2023 |
0.78(USD Billion) |
| Market Size 2032 |
1.65(USD Billion) |
| Compound Annual Growth Rate (CAGR) |
8.67% (2024 - 2032) |
| Report Coverage |
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Base Year |
2023 |
| Market Forecast Period |
2024 - 2032 |
| Historical Data |
2019 - 2023 |
| Market Forecast Units |
USD Billion |
| Key Companies Profiled |
Medtronic, GAMBRO, Fresenius SE Co. KGaA, DiaSorin S.p.A., Organ Recovery Systems, Inc., Toray Medical Co., Ltd., CaridianBCT, Inc., Cytosorbents Corporation, Terumo Corporation, Bellco, Asahi Kasei Corporation, Baxter International Inc., Nipro Corporation, Kaneka Corporation, B. Braun Melsungen AG |
| Segments Covered |
Drug Type, Route of Administration, Disease Indication, Distribution Channel, Regional |
| Key Market Opportunities |
Growing elderly population Increasing prevalence of xerostomia Rising demand for artificial saliva Technological advancements Government initiatives |
| Key Market Dynamics |
Aging population Rising incidence of cancer therapies Technological advancements |
| Countries Covered |
North America, Europe, APAC, South America, MEA |
Frequently Asked Questions (FAQ) :
The xerostomia therapeutics market size was around USD 0.78 billion in 2023 and is projected to reach USD 1.65 billion by 2032, exhibiting a CAGR of 8.67% during the forecast period.
North America is expected to dominate the xerostomia therapeutics market throughout the forecast period due to the high prevalence of xerostomia caused by factors such as cancer treatments, autoimmune diseases, and certain medications.
The increasing prevalence of xerostomia, rising demand for effective treatments, and growing awareness about the condition are the primary factors driving the growth of the xerostomia therapeutics market.
Xerostomia therapeutics are primarily used to relieve symptoms associated with dry mouth, such as difficulty speaking, swallowing, and eating, as well as to prevent dental problems caused by reduced saliva production.
Major players in the xerostomia therapeutics market include Biohaven Pharmaceuticals, Inc., Novartis AG, Sun Pharmaceutical Industries Ltd., and GlaxoSmithKline plc.
The xerostomia therapeutics market is anticipated to expand at a CAGR of 8.67% from 2024 to 2032.
Lack of awareness about xerostomia, limited treatment options, and reimbursement issues are some of the challenges faced by the xerostomia therapeutics market.
The rising prevalence of xerostomia, increasing demand for effective treatments, and growing awareness about the condition present significant growth opportunities for the xerostomia therapeutics market.
The development of new and more effective treatments, increasing adoption of personalized medicine, and growing emphasis on preventive care are key trends shaping the xerostomia therapeutics market.
The xerostomia therapeutics market is expected to witness steady growth over the coming years, driven by the rising prevalence of xerostomia, increasing demand for effective treatments, and growing awareness about the condition.
